33 results
10-K
2023 FY
TCBP
TC BioPharm (Holdings) plc
1 Apr 24
Annual report
5:11pm
and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.
Collaborations, whether through joint … of the convertible loan note under ASC 815-Derivatives and Hedging. Where there are outstanding amounts under the convertible loan note, these are recorded
6-K
EX-10.4
TCBP
TC BioPharm (Holdings) plc
21 Dec 23
TC BioPharm Announces Pricing of $3.5 Million Public Offering
5:14pm
” transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during … with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders’ equity interests
F-1/A
EX-10.7
TCBP
TC BioPharm (Holdings) plc
12 Dec 23
Registration statement (foreign) (amended)
9:34pm
Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during … the periods that the value of the Warrant ADSs deliverable with respect to Securities are being determined, and (z) such hedging activities (if any
424B3
TCBP
TC BioPharm (Holdings) plc
8 Nov 23
Prospectus supplement
4:05pm
or other hedging transactions, whether through an options exchange or otherwise;
a combination of any such methods of sale; or
any other method … of the securities or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which
F-3/A
TCBP
TC BioPharm (Holdings) plc
2 Nov 23
Shelf registration (foreign) (amended)
1:11pm
or other hedging transactions, whether through an options exchange or otherwise;
a combination of any such methods of sale; or
any other method permitted … of the securities or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which may
F-3
zb13edbufkpa
29 Sep 23
Shelf registration (foreign)
4:05pm
6-K
EX-10.3
uxxji kqy8fy
30 Mar 23
TC BioPharm Announces Pricing of $5.5 Million Public Offering
5:10pm
6-K
EX-10.4
6slwvf
30 Mar 23
TC BioPharm Announces Pricing of $5.5 Million Public Offering
5:10pm
424B4
b8zq330wd
29 Mar 23
Prospectus supplement with pricing info
5:01pm
424B3
u3p3v69a4bxk
27 Dec 22
Prospectus supplement
4:05pm
F-1
0g6p pq42
12 Dec 22
Registration statement (foreign)
4:02pm
6-K
EX-10.5
vus1e
30 Nov 22
Current report (foreign)
8:58am
6-K
EX-10.4
f7ys vy9z3h46
30 Nov 22
Current report (foreign)
8:58am
20-F
0dnpv
13 May 22
Annual report (foreign)
3:56pm
POS EX
EX-1.1
oc6rppt8464orhuvyco
8 Mar 22
Additional exhibits for listing
5:24pm
424B4
iyb9ajvpsw zw4gz
2 Mar 22
Prospectus supplement with pricing info
12:03pm
424B4
040gbscz
14 Feb 22
Prospectus supplement with pricing info
5:10pm
424B4
w1d elj1f
14 Feb 22
Prospectus supplement with pricing info
12:00am
F-1/A
EX-1.1
nd3i6svvldz5bg
9 Feb 22
Registration statement (foreign) (amended)
5:01pm